- Home
- CELC vs CPAC Comparison
CELC vs CPAC Comparison
Compare CELC & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- CPAC
- Stock Information
- Founded
- CELC 2011
- CPAC 1949
- Country
- CELC United States
- CPAC Peru
- Employees
- CELC N/A
- CPAC N/A
- Industry
- CELC Medical Specialities
- CPAC Building Materials
- Sector
- CELC Health Care
- CPAC Industrials
- Exchange
- CELC Nasdaq
- CPAC Nasdaq
- Market Cap
- CELC 440.0M
- CPAC 493.6M
- IPO Year
- CELC 2017
- CPAC 2012
- Fundamental
- Price
- CELC $13.04
- CPAC $6.10
- Analyst Decision
- CELC Strong Buy
- CPAC Sell
- Analyst Count
- CELC 6
- CPAC 2
- Target Price
- CELC $30.67
- CPAC $6.20
- AVG Volume (30 Days)
- CELC 196.9K
- CPAC 8.7K
- Earning Date
- CELC 08-13-2025
- CPAC 07-21-2025
- Dividend Yield
- CELC N/A
- CPAC 8.19%
- EPS Growth
- CELC N/A
- CPAC 15.59
- EPS
- CELC N/A
- CPAC 0.13
- Revenue
- CELC N/A
- CPAC $545,786,617.00
- Revenue This Year
- CELC N/A
- CPAC N/A
- Revenue Next Year
- CELC N/A
- CPAC N/A
- P/E Ratio
- CELC N/A
- CPAC $9.32
- Revenue Growth
- CELC N/A
- CPAC 2.78
- 52 Week Low
- CELC $7.58
- CPAC $5.10
- 52 Week High
- CELC $19.77
- CPAC $6.65
- Technical
- Relative Strength Index (RSI)
- CELC 60.10
- CPAC 62.92
- Support Level
- CELC $12.48
- CPAC $5.82
- Resistance Level
- CELC $13.60
- CPAC $6.65
- Average True Range (ATR)
- CELC 0.74
- CPAC 0.15
- MACD
- CELC 0.04
- CPAC 0.01
- Stochastic Oscillator
- CELC 75.91
- CPAC 40.22
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About CPAC Cementos Pacasmayo S.A.A. (Each representing five)
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.